AbbVie (ABBV) Q4 2025 Earnings
How Did ABBV Stock React to Q4 2025 Earnings?
S&P 500 over the same 30 days: −1.15%.
Did ABBV Beat Earnings? Q4 2025 Results
Yes. AbbVie reported Q4 2025 earnings of $2.71 a share on Feb 4, 2026, beating the $2.65 consensus estimate by 2.2%. Revenue was $16.6B against a $16.4B estimate.
AbbVie closed out 2025 on a mixed note, posting a headline earnings miss that masked genuinely strong revenue momentum underneath. Fourth-quarter adjusted diluted EPS came in at $2.71, falling well short of the $3.35 consensus estimate by 19.10%, largely due to $0.71 per share in acquired IPR&D and milestones charges tied to the company's pipeline investments. Revenue, however, told a more encouraging story, reaching $16.62 billion for the quarter, up 10.0% year over year and edging past the $16.42 billion consensus by 1.22%. The growth engine was AbbVie's immunology franchise, where Skyrizi surged 32.5% to $5.01 billion in Q4, more than compensating for Humira's continued 25.9% decline to $1.25 billion. Some analysts have flagged concerns about growth trajectories beyond 2028 as competitive pressures loom, but management signaled confidence in near-term momentum by guiding 2026 adjusted diluted EPS to a range of $14.37 to $14.57, reflecting expectations for meaningful earnings acceleration in the year ahead.
- Skyrizi revenue growth of 32.5% in Q4, becoming AbbVie's largest product at $5.0 billion in quarterly revenue
- Rinvoq revenue growth of 29.5% in Q4 driven by both U.S. and international expansion
- Neuroscience portfolio growth of 17.9% led by Vraylar, Botox Therapeutic, and migraine franchise
- Strong operational execution offsetting continued Humira biosimilar erosion
- Qulipta grew 42.6% in Q4 as migraine franchise continues rapid expansion
“2025 was another outstanding year for AbbVie. We delivered record net sales in just the second full year following the U.S. Humira loss of exclusivity, underscoring the strength of our diversified growth platform. We also advanced promising new treatments for patients while enhancing the breadth and depth of our pipeline with strategic investments.”
AbbVie CEO, on the earnings call
What Was AbbVie's Outlook in Q4 2025?
AbbVie issued full-year 2026 adjusted diluted EPS guidance of $14.37 to $14.57, excluding any impact from acquired IPR&D and milestones that may be incurred during 2026. Management expects another year of robust growth based on the company's strong fundamentals and momentum across its diversified portfolio.
ABBV YoY Financials
| Metric | Q4 2025 | Q4 2024 | Year over year |
|---|---|---|---|
| Revenue | $16.6B | $15.1B | +10.0% |
| Operating Income | $4.5B | $899.9M | +405.0% |
| Net Income | $1.8B | $21.5M | +8,354.6% |
ABBV Revenue by Segment
ABBV Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.